PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant pancreatic cancer patients

Abstract

Background: Partly due to the limited effect of chemotherapy or other therapeutic strategies, which may due to the insufficient known of the tumor promotion markers and targets, pancreatic cancer (PC) holds the position of one of the most malignant tumors. This study aims to found a diagnosis/therapeutic molecule that can predicted the prognosis in pancreatic cancer with different gene background. Methods: TCGA PAAD based single nucleotide polymorphisms and gene expression data was used to find the different expression genes (DEGs) between KRAS/TP53 mutant samples and no gene mutation samples. GSEA based KEGG analysis and R based GO or immune cell invasion assay were used to explore above DEGs involved pathways. The single center pancreatic cancer cohort accompanied with next generation sequence testing was used to verified the TGCA PAAD based bioinformatic results. Results: Firstly, we found pancreatic cancer patients harbored KRAS and/or TP53 gene mutation have a poor overall survival. Besides, the enrichment analysis showed that mutant KRAS/TP53 was correlated with pancreatic cancer tumor-promotion-related pathways and immune microenvironment. Next, we detected that prostate stem cell antigen (PSCA) was one of the most differential genes in KRAS/TP53 mutant pancreatic cancer tissues. Indeed, the bioinformatic analysis and our clinical data showed PSCA was a biomarker of poor prognosis in pancreatic cancer. Conclusion: PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant pancreatic cancer patients.